Evidence map›Paper›PMID 41541779›Full record

ArticleKidney international reports2026

Clinicopathological Spectrum and Treatment Outcomes of Cryofibrinogen-Associated Nephropathies.

Julien Dang, Stanislas Faguer, Noémie Jourde-Chiche, Vincent Javaugue, Frank Bridoux, Bénédice Puissant, Xavier Heim, Jean-Jacques Boffa, Hélène François, Yanis Tamzali and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Julien DangAssistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré, Service de Néphrologie et Dialyse, Boulogne-Billancourt, France.
Stanislas FaguerHôpital de Rangueil, Service de Néphrologie et Transplantation d'Organes, Toulouse, France.
Noémie Jourde-ChicheAix-Marseille Univ, C2VN, INSERM, INRAE, Hôpital de la Conception, Service de Néphrologie et Transplantation rénale, Marseille, France.
Vincent JavaugueHôpital de Poitiers, Service de Néphrologie, Hémodialyse et Transplantation Rénale, Poitiers, France.
Frank BridouxHôpital de Poitiers, Service de Néphrologie, Hémodialyse et Transplantation Rénale, Poitiers, France.
Bénédice PuissantHôpital de Purpan, Laboratoire d'Immunologie - Institut Fédératif de Biologie, Toulouse, France.
Xavier HeimHôpital de la Timone, Biogénopôle - Immunologie, Marseille, France.
Jean-Jacques BoffaAP-HP, Hôpital Tenon, Service de Néphrologie et Dialyse, Paris, France.
Hélène FrançoisSorbonne Université, INSERM CIMI U1135, AP-HP, Hôpital Pitié-Salpêtrière, Service de Néphrologie, Unité de Transplantation Rénale, Paris, France.
Yanis TamzaliSorbonne Université, INSERM CIMI U1135, AP-HP, Hôpital Pitié-Salpêtrière, Service de Néphrologie, Unité de Transplantation Rénale, Paris, France.
Evangéline PilleboutAP-HP, Hôpital Saint-Louis, Service de Néphrologie et Transplantation Rénale, Paris, France.
Eric DaugasAP-HP, Hôpital Bichat, Service de Néphrologie, Paris, France.
Renato MonteiroAP-HP, Université Paris Cité, INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France.
Laurent DanielAix-Marseille Univ, C2VN, INSERM, INRAE, Hôpital de la Timone, Service d'Anatomie Pathologie, Marseille, France.
Kévin ChevalierUniversité Paris Cité, INSERM U790, Centre de Recherche Cardiovasculaire de Paris, France.
Vincent AudardAP-HP, Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Créteil, France.
Margaux Van WynsbergheHôpitaux de Rouen, Service de Néphrologie, Rouen, France.
Dominique GuerrotHôpitaux de Rouen, Service de Néphrologie, Rouen, France.
Mathieu LegendreCHU de Dijon, Service de Néphrologie, Dijon, France.
Sébastien SangesUniv. Lille, Inserm, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille, France.
Céline LebasHôpital Claude Huriez, Service de Néphrologie, Lille, France.
Nans FlorensHôpitaux Universitaires de Strasbourg, Service de Néphrologie, Dialyse et Transplantation, Strasbourg, France.
Charles RonsinCentre Hospitalier Universitaire de Nantes, Service de Néphrologie et Immunologie, Nantes, France.
Charlotte MussiniAP-HP, Hôpital de Bicêtre, Service d'Anatomie Pathologique, Le Kremlin-Bicêtre, France.
Sophie FerlicotAP-HP, Hôpital de Bicêtre, Service d'Anatomie Pathologique, Le Kremlin-Bicêtre, France.
Sarah MouawadAP-HP, Hôpital de Bicêtre, Service de Néphrologie et Transplantation, Le Kremlin-Bicêtre, France.
Renaud SnanoudjAP-HP, Hôpital de Bicêtre, Service de Néphrologie et Transplantation, Le Kremlin-Bicêtre, France.
Ana PimentelAssistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré, Service de Néphrologie et Dialyse, Boulogne-Billancourt, France.
Marie EssigAssistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré, Service de Néphrologie et Dialyse, Boulogne-Billancourt, France.
Marc Pineton De ChambrunAP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Paris, France.
Pascale Ghillani-DalbinAP-HP, Hôpital Pitié-Salpêtrière, Service d'Immunologie, Paris, France.
Benjamin TerrierAP-HP, Hôpital Cochin, Service de Médecine Interne, Paris, France.
Mohamad ZaidanAP-HP, Hôpital de Bicêtre, Service de Néphrologie et Transplantation, Le Kremlin-Bicêtre, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cryofibrinogen-associated nephropathy (CFN) is a very rare disease. Only few data are available about the clinicopathological presentation and treatment outcomes. Methods: Patients with cryofibrinogenemia (CF) diagnosed in French expert laboratories, and kidney biopsy findings suggestive of CFN (pauci-immune membranoproliferative glomerulonephritis [MPGN], thrombotic microangiopathy [TMA] and/or indirect signs of ischemia) were retrospectively included. Estimated glomerular filtration rate (eGFR), urinary protein-to-creatinine ratio (UPCR), and specific treatments were collected. Renal response (RR) was defined as a reduction of UPCR to < 0.5 g/g (or decrease > 50% if > 3 g/g at baseline) and an improvement of eGFR > 30% (if < 60 ml/min per 1.73 m Results: Among 2545 patients with CF, 232 (9%) underwent kidney biopsy, and only 28 (1%) had histological findings suggestive of CFN. Ten patients (36%) were female, and median age was 62 (interquartile range [IQR]: 49-71) years. eGFR at diagnosis was 21 (14-44) ml/min per 1.73 m Conclusion: Our study, to the best of our knowledge, described for the first time the prevalence and the clinicopathological spectrum of CFN, which might be a very rare and underrecognized form of MG of renal significance presenting with pauci-immune MPGN ot TMA. IS are effective in most cases.

Indexed as

cryofibrinogenglomerular diseasemembranoproliferative glomerulonephritismonoclonal gammopathy of renal significancenephrotic syndromethrombotic microangiopathy

Identifiers

PMID41541779
PMCPMC12799572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.